Diabetic Eye Disease: What's Next for Your Patients?
Diabetic retinopathy may be proliferative or nonproliferative, and patients may present with or without macular edema. And then there's the possibility that one patient's disease is VEGF-mediated whereas another's is not. With all of these factors, it's important to understand which therapeutic options work best for particular patients. Nathan Steinle, MD, reviews data from the BOULEVARD trial, a phase 2 study evaluating faricimab (Genentech/Roche) in patients with DME. And Rishi Singh, MD, parses the 52-week data from the PANORAMA trial, which evaluated the effect of aflibercept (Eylea, Regeneron) in approximately 400 patients with high-risk NPDR without DME. This editorially independent podcast is supported with advertising.